Pricing Log in Create free account
Saturday 17 October 2026 Export ZTS’s income statement to Excel — free account

Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.

79.20 0.78 +0.99%
Market cap
$32.4B
P/E
13.0×
Fwd P/E
12.3×
Dividend yield
2.64%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Zoetis Inc. (ZTS) P/S ratio

Alert me on P/S ratio

As of 16 October 2026, Zoetis Inc. (ZTS) trades at a P/S ratio of 3.5×. Over the past ten years it has ranged from 3.0× (October 2026) to 15.4× (December 2021); the current reading is higher than 3% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.1× and in line with the Healthcare sector median of 3.4×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 5.9× (26.29%)
FY2024 8.0× (24.65%)
FY2023 10.6× 24.50%
FY2022 8.5× (42.75%)
FY2021 14.9× 26.27%
FY2020 11.8× 16.63%
FY2019 10.1× 42.50%
FY2018 7.1× 7.07%
FY2017 6.6× 21.91%
FY2016 5.4× 8.15%

Quarterly newest first

Period P/S ratio Change
Jun 2026 3.2× (39.82%)
Mar 2026 5.2× (11.17%)
Dec 2025 5.9× (14.61%)
Sep 2025 6.9× (6.76%)
42 more quarters

Against its own ten years

Low 3.0× High 15.4×
Ten-year median 8.1×
Current reading's percentile 4

P/S ratio against peers

Company P/S ratio
VTRS Viatris Inc. compare 1.5×
TAK Takeda Pharmaceutical Co. compare 2.1×
ELAN Elanco Animal Health Incorporated compare 2.3×
HLN Haleon PLC Sponsored ADR compare 2.6×
TEVA Teva Pharmaceutical Industries Ltd. compare 2.8×
RDY Dr. Reddy's Laboratories Ltd compare 3.0×
ZTS Zoetis Inc. 3.5×
NBIX Neurocrine Biosciences, Inc. compare 4.1×
UTHR United Therapeutics Corporation compare 7.2×
Drug Manufacturers Specialty & Generic industry median 2.1×
Healthcare sector median 3.4×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on ZTS